Ulcerative Colitis
Advisory Board
Emanuelle A. Bellaguarda, MD
Assistant Professor of Medicine, Gastroenterology and Hepatology; Program Director, Inflammatory Bowel Disease Fellowship, Northwestern University Feinberg School of Medicine, Chicago, Illinois
Dr Bellaguarda specializes in the treatment of patients with inflammatory bowel diseases, Crohn's disease and ulcerative colitis. She also leads the immune checkpoint inhibitor enterocolitis toxicity service at Northwestern Memorial Hospital. Her research areas of interest include therapeutic drug monitoring, and she has participated in more than 20 clinical trials. Dr Bellaguarda also directs the Advanced Fellowship in Inflammatory Bowel Disease program at Feinberg School of Medicine. She is a member of the American College of Gastroenterology, American Gastroenterological Association, and the Crohn's & Colitis Foundation of America.
Disclosures
Emanuelle A. Bellaguarda, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; Lilly; Janssen
Serve(d) as a speaker or a member of a speakers bureau for: AbbVie; Lilly; Pfizer; Celltrion
Millie D. Long, MD, MPH
Professor of Medicine, Gastroenterology and Hepatology; Director, Gastroenterology and Hepatology Fellowship Program, University of North Carolina at Chapel Hill
Dr Long is board certified in internal medicine, preventive medicine, and gastroenterology. Her clinical practice is at the University of North Carolina Multidisciplinary Inflammatory Bowel Diseases (IBD) Center. Dr Long's research interests include prevention of complications of inflammatory bowel disease, women's health, and clinical epidemiology. She is the current co–editor-in-chief of The American Journal of Gastroenterology and serves as an invited reviewer for publications such as The New England Journal of Medicine, Inflammatory Bowel Diseases, and Gastroenterology. She has contributed to over 200 peer-reviewed publications, book chapters, and review articles. Dr Long is a fellow of the American College of Gastroenterology, where she serves on the Board of Trustees. She is also a fellow of the American Gastroenterological Association and the Crohn's & Colitis Foundation.
Disclosures
Millie D. Long, MD, MPH, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; Takeda; Pfizer; Janssen; BMS; Lilly; Prometheus; Roivant; Target RWE; Intercept
Received research grant from: Takeda; Pfizer; Lilly
Ryan C. Ungaro, MD
Associate Professor of Medicine; Director of Clinical Research, Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY
Dr Ungaro is a clinician and researcher who specializes in the care of patients with ulcerative colitis and Crohn's disease. He is director of Comprehensive Care for the Recently Diagnosed IBD Patient (COMPASS-IBD) program at the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center. The program provides interdisciplinary care for recently diagnosed patients. In his research, Dr Ungaro focuses on understanding the effects of early intervention on inflammatory bowel disease outcomes, precision-medicine approaches to improve risk stratification and optimization of therapy for patients, and understanding preclinical irritable bowel disease with the goal of predicting and eventually preventing the condition. He has served on the American Gastroenterological Association Research Awards Panel and as co-chair of the Crohn's & Colitis Foundation Rising Educators Academics and Clinicians Helping IBD (REACH-IBD) committee.
Disclosures
Ryan C. Ungaro, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; Bristol Myers Squibb; Celltrion; Lilly; Janssen; Pfizer; Roivant; Takeda
Received research grant from: AbbVie; Boehringer Ingelheim; Bristol Myers Squibb; Lily; Pfizer